<DOC>
	<DOCNO>NCT02305979</DOCNO>
	<brief_summary>The purpose project assess efficacy loratadine decrease incidence severity bone pain follow G-CSF administration patient hematologic malignancy , patient undergo mobilization hematopoietic progenitor cell , patient undergo autologous hematopoietic cell transplant . This different patient population assess current clinical trial .</brief_summary>
	<brief_title>Evaluation Loratadine G-CSF Induced Bone Pain Patients With Hematologic Malignancies</brief_title>
	<detailed_description>Objectives The primary objective determine incidence bone pain follow G-CSF administration patient hematologic malignancy , patient undergo mobilization hematopoietic progenitor cell , patient undergo autologous hematopoietic cell transplant . Incidence determine via patient-reported incidence follow G-CSF administration . Secondary objective include determine efficacy loratadine bone pain prevention indicate decrease incidence decrease severity ( question 4 5 survey ) .</detailed_description>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Receiving GCSF institution practice change Receiving GCSF one follow indication : Prevention/treatment neutropenia along treatment leukemia lymphoma Mobilization hematopoietic progenitor cell Neutropenia prevention follow autologous hematopoietic cell transplant Took loratadine per protocol GCSF administration Completed survey Taking daily antihistamine allergy , asthma , indication , include bone pain Taking daily NSAIDs , exception aspirin , chronic condition Treatment solid tumor cancer Receiving bone modify agent bone pain associated metastatic disease chronic condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>